VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

IMS 2022 | Efficacy of trametinib in patients with multiple myeloma with NRAS and KRAS mutations

Meral Beksac, MD, Ankara University, Ankara, Turkey, talks on the efficacy of trametinib in patients with triple-class refractory multiple myeloma who are KRAS or NRAS-mutated. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter